• Oversubscribed Series C led by S32 with backing from NVIDIA and others
• Funding will advance a pipeline of EDEN-designed therapeutics, starting with in vivo cell therapy, and expand pharmaceutical partnerships
• The company has demonstrated strong preclinical results across multiple modalities and disease areas

LONDON and BOSTON, Sept. 23, 2026...